3 Issued U.S. Patents · Active Through 2037

A Patented Platform for
Transdermal Glutathione
Delivery

The only issued patent estate protecting transdermal glutathione delivery in both cream and patch form — spanning cosmeceutical, nutraceutical, pharmaceutical, and clinical markets from a single protected technology base.

Cosmeceutical Nutraceutical Pharmaceutical Sports & Longevity Clinical & Oncology
Request Partnership Deck ↓ Explore the Platform
3
Issued U.S. Patents
2037
Patent Expiration
19+
Years Clinical Experience
Franz Cell
Independent Permeation Validation
Day 14
Visible Clinical Improvement
5
Patented Therapeutic Outcomes

As Seen In

VOGUE
ELLE
SHAPE
HOUSE & GARDEN
DAILY VANITY
WOMEN OF INSPIRATION
The Platform

One Protected Base.
Unlimited Commercial Reach.

GlutaTherapy has developed the only issued U.S. patent estate covering transdermal delivery of glutathione in both topical cream and adhesive patch form — protected through 2037.

While most glutathione products rely on oral supplementation (poor bioavailability) or IV injection (requiring clinical administration), GlutaTherapy's platform enables localized, targeted transdermal delivery — absorbed directly through the skin without injection or oral supplementation.

Three continuation patents form a layered defensive wall. A competitor cannot take the formulation and use a different delivery format, nor can they copy the delivery approach with a different formulation. The platform is protected in its entirety.

The patent claims span five independently patented therapeutic outcomes — creating commercial applications across multiple markets, all from the same protected technology base.

US 10,314,779 B2 · Granted June 2019
Transdermal Glutathione Delivery — Foundation Patent
Core formulation claim covering cream and patch delivery using glutathione with penetration-enhancing co-formulants. Establishes the foundational IP position.
Active · Expires 2037
US 10,548,830 B2 · Granted February 2020
Expanded Formulation & Delivery Variations
Continuation broadening formulation scope — wider range of active components, additional carrier combinations, expanded delivery variations. Closes competitor design-around pathways.
Active · Expires 2037
US 12,048,729 B2 · Granted July 2024
Advanced Liposomal Delivery Technology
Most recent and most advanced patent. Extends the platform into liposomal encapsulation — the cutting edge of transdermal bioavailability — further protecting the platform against next-generation competitors.
Active · Expires 2037
Delivery Format

Cream or Patch — Both Protected

Format 1

Transdermal Cream

Latex-free, hypoallergenic topical formulation applied directly to skin. Suitable for cosmeceutical retail, clinical, and aesthetic medicine channels. Broad consumer and professional market applicability.

Format 2

Adhesive Patch

Controlled, sustained transdermal delivery via hypoallergenic adhesive patch. Opens pharmaceutical, nutraceutical, clinical, and institutional channels. Enables precise dosing and extended release profiles.

Therapeutic Applications

Five Patented Outcomes.
Six Commercial Markets.

The patent claims cover five independently validated therapeutic outcomes — each opening distinct commercial channels with their own buyer ecosystems and revenue opportunities.

🔬

Dermatologic & Aesthetic

Reduction of facial wrinkles, skin brightening, hyperpigmentation correction, and barrier repair. Minimum 10% increase in skin moisture retention documented in patent claims.

CosmeceuticalMed SpaAesthetics
🩹

Wound Care & Scar Repair

Keloid reduction, surgical scar remodeling, burn scar treatment, trauma scarring, and advanced tissue repair. Visible improvement documented at Day 14 in investigator pilot.

ClinicalSurgicalWound Care
😴

Sleep Regulation

Patented claim for regulation of circadian sleep/wake cycle. Opens the sleep supplement and wellness market — one of the fastest-growing nutraceutical categories globally.

NutraceuticalWellnessConsumer
⚡

Energy & Cognitive Performance

Patented claims for increased energy during awake periods and improved concentration. Directly applicable to sports nutrition, biohacking, and functional wellness markets.

Sports NutritionLongevityBiohacking
💊

Joint & Muscular Pain Relief

Patented reduction of joint and muscular pain without injection or oral supplementation. Applicable to sports recovery, pain management, and pharmaceutical channels.

PharmaceuticalSportsRecovery
🏥

Clinical & Oncology Support

Glutathione depletion is well-documented in oncology patients. Transdermal delivery without injection opens institutional clinical channels including radiation recovery and oncology-supportive care.

PharmaceuticalOncologyInstitutional
Patented Outcomes

What The Patents Protect

Six therapeutic outcomes are explicitly claimed across the patent family — each independently protecting a commercial market segment.

⚕️

Scar & Keloid Reduction

Clinically documented — reduced inflammation, redness & flatter scar profile at Day 14

😴

Sleep Regulation

Circadian rhythm & sleep/wake cycle

⚡

Energy & Concentration

Increased energy & cognitive focus during awake periods

✨

Facial Wrinkle Reduction

+10% skin moisture retention, anti-aging

🦴

Joint & Muscle Pain

Non-injection, non-oral pain relief pathway

🩹

Tissue & Wound Repair

Wound healing, dermatologic repair & advanced skin restoration

Pilot Evidence

Validated. Documented. Ready.

Day 1 - Keloid Scar Day 1
Day 14 - Keloid Scar Day 14

Keloid scar · Post-melanoma excision · Clinical photography available under NDA

Investigator Pilot · 4-Week

Visible Results.
Measurable Outcomes.

  • ✓
    Reduced inflammation
  • ✓
    Decreased redness
  • ✓
    Flatter scar profile
  • ✓
    Reduced itching and pain (patient-reported)
  • ✓
    Improved tissue texture

Full clinical photography and evaluation documentation available to qualified buyers under NDA.

Franz Cell Testing

Independent permeation validation confirming transdermal delivery efficacy

Stability Testing

Formulation stability confirmed — commercially ready for scale

Manufacturing Ready

Manufacturing pathways established and validated

Why This Technology Is Different

Solving Glutathione's
Biggest Problem

The Problem: Glutathione Bioavailability
Oral and IV delivery are limited, invasive, or impractical at scale
Oral Supplementation
Poor bioavailability — destroyed by digestive enzymes before absorption
IV / Injection
Requires clinical setting — not scalable for consumer or nutraceutical markets
GlutaTherapy Transdermal Platform
Direct skin absorption — no injection, no degradation, targeted delivery. Protected through 2037.
Liposomal Enhancement (Patent 3)
Most advanced formulation — liposomal encapsulation for maximum cellular uptake

A Platform, Not A Product

Most IP acquisitions involve a single product with a single application. GlutaTherapy is fundamentally different — it is a platform technology with one protected delivery mechanism applicable across six distinct commercial markets.

A strategic acquirer doesn't inherit one revenue stream. They inherit the ability to launch into cosmeceutical, nutraceutical, pharmaceutical, sports nutrition, longevity, and clinical markets — all from a single IP transaction.

The Liposomal Advantage

Patent 3 (granted 2024) introduces liposomal encapsulation — the most advanced transdermal delivery technology currently available. Liposomal delivery dramatically improves cellular uptake and is the subject of significant R&D investment industry-wide.

GlutaTherapy already has this protected. Competitors building toward liposomal glutathione delivery must navigate an issued patent estate that extends through 2037.

Continuation Patent Strategy

The three patents are not separate inventions — they are a layered defensive wall built on a single priority date (May 2017). Each continuation closes a potential design-around pathway. A competitor cannot use the formulation with a different delivery format, nor copy the delivery approach with a modified formulation.

The IP position must be licensed or acquired in its entirety — creating a clean, single-transaction opportunity for a strategic buyer.

Target Markets

Strategic Buyer Categories

The platform's multi-outcome patent claims create four distinct buyer ecosystems — each with independent budget, distribution infrastructure, and strategic rationale for acquisition.

Market 1

Cosmeceutical & Aesthetic

Anti-aging, skin brightening, hyperpigmentation, scar aesthetics, and post-procedure recovery. Topical cream format ideal for retail, professional, and med spa channels. Glutathione is one of the most searched aesthetic ingredients globally.

Target buyers: Obagi Medical, SkinMedica, iS Clinical, Colorescience, regional cosmeceutical brands
Market 2

Nutraceutical & Longevity

Sleep regulation, energy, cognitive performance, and systemic antioxidant support via patch format. The longevity and biohacking sector is actively acquiring proprietary delivery IP. Transdermal patch delivery is a premium differentiation signal in this market.

Target buyers: Thorne, Designs for Health, Life Extension, Metagenics, biohacking brands
Market 3

Pharmaceutical & Clinical

Non-injection glutathione delivery for clinical settings — oncology support, wound management, radiation recovery, and institutional channels. The pharmaceutical channel represents the highest-value licensing opportunity given therapeutic claim breadth.

Target buyers: Pharma companies with transdermal pipelines, wound care specialists, oncology-adjacent companies
Market 4

Sports Nutrition & Recovery

Joint and muscular pain relief, energy, and recovery — all patented claims with direct sports nutrition applicability. Transdermal delivery is a premium format in this market, commanding higher price points and strong brand differentiation.

Target buyers: Sports nutrition brands, recovery technology companies, professional sports partnerships
Partnership Structures

How We Work Together

GlutaTherapy is open to multiple engagement structures depending on the strategic fit and commercial goals of the partner.

Option 01

Full IP Acquisition

Complete purchase of all three patents and Glutatherapy™ trademark. Clean transaction, full ownership transfer.

Option 02

Exclusive License

Exclusive licensing rights by market category, geography, or application — with retained patent ownership.

Option 03

Strategic Co-Development

Joint development partnership to expand the platform into new therapeutic areas or delivery formats.

Option 04

Distribution & Joint Venture

Commercial distribution agreements or joint venture structures for specific markets or territories.

The Inventor

Built From Clinical Practice

GlutaTherapy was founded by Rachel Sarah Levine, MSc, DSHOMED — a clinician with 19 years of experience treating complex chronic conditions using integrative and naturopathic medicine.

The platform was developed from firsthand clinical frustration with existing glutathione delivery methods — and built to solve a real, documented problem in both clinical and consumer health contexts.

The result is a patent estate grounded in clinical reality, validated independently, and commercially ready.

MSc, DSHOMED — Advanced clinical credentials
19+ years clinical experience in chronic disease
Sole inventor — all three U.S. patents
Independent Franz Cell permeation validation
Stability testing completed — commercially ready
Manufacturing pathways established
Glutatherapy™ trademark registered
What Users Say

Real Results. Real People.

Previously commercialized under the Susona brand — strong consumer reviews at launch demonstrate real market demand and product efficacy.

"When I started using Glutatherapy™, I felt like I was putting medicine on my face. I am in my early 60s and for the first time, my wrinkles and my age spots reduced!"

CB
Carmel Boss
Founder, CoAbode.com

"I rarely wear eye makeup due to my blepharitis. Once I started using Susona, all the inflammation went away! My skin is absolutely glowing — all my friends have complimented me."

KG
Katherine G.
Los Angeles

"I'm obsessed with this serum! I use it day and night and feel an immediate energy boost. My partner compliments me that my skin looks super fresh and glowy."

GB
Gabriela B.
Documentary Film Maker

"My daughter had a bad skin rash. After using Susona for a couple of days, her skin showed major improvement. Thank you Susona!"

RK
Rob K.
Co-Host, Real Dad Talk
Get In Touch

Ready to Explore a Partnership?

GlutaTherapy is actively engaging qualified strategic partners across all market categories. Initial conversations are confidential and conducted under mutual NDA.

rachel@glutatherapy.com →
Direct · Confidential · Responded within 48 hours
Request Partnership Deck

All inquiries are confidential. NDA available upon request.

Thank You

Your inquiry has been received. We'll be in touch within 48 hours to discuss next steps.